Drug
Multivalent Pneumococcal Vaccine Formulation 1
Multivalent Pneumococcal Vaccine Formulation 1: highest development phase Phase 1/2, developed by Pfizer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Pfizer
Trials
| Drug | Phase | Indication |
|---|---|---|
| Multivalent Pneumococcal Vaccine - Formulation 1 NCT06182124 | Phase 1/2 | Pneumococcal Disease |
Latest
No recent events.
Follow Multivalent Pneumococcal Vaccine Formulation 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.